Sector: health
Conviction from: NASDAQ
52-week range: 34.6364.38
Royalty Pharma acquires royalty interests in approved and development-stage prescription drugs, funding biopharmaceutical innovation in exchange for future royalty streams.
4 tracked filer(s) hold this · 1 opened, 1 added, 2 trimmed in 30-JUN-2026
Aggregate 13FScore 72 — mean of 4 scored holder(s) · buyers (new/add) avg 74. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Bridgewater | 56 | New buy | 219,687 | $12,317,850 | 0.1% |
| Pat Dorsey / Dorsey Asset | 92 | Added +8% | 2,456,528 | $137,737,525 | 8.8% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -15% | 610,736 | $34,243,968 | 0.0% |
| Steve Cohen / Point72 | 76 | Trimmed -78% | 106,549 | $5,974,202 | 0.0% |
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-02-20 | SCHEDULE 13D/A | Severgnini Achille G. | 5.7% | Med | filing |
2 disclosed trade(s) by 1 filer(s).